Business Context and Reporting Period
Company: LeonaBio, Inc. (formerly Athira Pharma, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: LeonaBio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The company recently rebranded in January 2026 to reflect a strategic shift following the in-licensing of lasofoxifene in December 2025. It operates as a single segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 | Three Months Ended June 30, 2026 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(51,955) | $(16,109) | $(19,007) |
| Loss Per Share (Basic & Diluted) | $(2.43) | $(4.12) | $(0.80) |
| Operating Expenses | $36,667 | $16,827 | $19,453 |
| Research & Development (R&D) | $23,964 | $7,963 | $12,702 |
| General & Administrative (G&A) | $13,457 | $8,864 | $6,576 |
| Cash Used in Operating Activities | $(37,861) | $(21,664) | N/A |
| Cash, Cash Equivalents & Investments | $51,067 | $69,907 | $51,067 |
| Total Assets | $56,894 | $92,151 | $56,894 |
| Total Liabilities | $23,299 | $64,361 | $23,299 |
| Stockholders' Equity | $33,595 | $27,790 | $33,595 |
Note: The company has no revenue. The significant decrease in liabilities from the prior year is primarily due to the reclassification of the Sermonix pre-funded warrant from a liability to equity.
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses increased by 118% year-over-year (from $16.8M to $36.7M). This was driven by a 201% increase in R&D expenses, primarily due to the initiation of the Phase 3 ELAINE-3 trial for lasofoxifene ($17.7M in costs for the six months ended June 30, 2026, compared to $0 in the prior year).
- Net Loss Expansion: Net loss increased by 223% to $52.0M. While operating losses widened, the net loss was partially mitigated by a $16.3M non-cash gain from the change in fair value of the Sermonix pre-funded warrant prior to its reclassification to equity.
- Liquidity Position: Cash and investments decreased by approximately $18.8M to $51.1M due to operating cash burn of $37.9M, partially offset by net proceeds from a December 2025 private placement of approximately $90M.
- Balance Sheet Restructuring: Current liabilities decreased significantly from $47.5M to $7.8M. This is largely attributable to the removal of the $37.5M Sermonix pre-funded warrant liability after stockholder approval allowed its reclassification to equity in March 2026.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management states that existing cash, cash equivalents, and investments ($51.1M) may not be sufficient to fund operating expenses and capital expenditure requirements through at least the next 12 months. This raises substantial doubt about the company's ability to continue as a going concern.
- Capital Raising Constraints: The company is currently ineligible to use Form S-3 for registered offerings due to a failure to timely file a Current Report on Form 8-K. This ineligibility extends through December 2026, impairing the ability to raise capital expeditiously via its At-The-Market (ATM) facility.
- Unusual Items:
- Sermonix Warrant Reclassification: A $53.8M liability was reclassified to equity in March 2026 following stockholder approval, resulting in a $16.3M non-cash gain in the six-month period.
- Milestone Liability: A $14.4M liability remains on the balance sheet related to potential milestone payments to Sermonix Pharmaceuticals, Inc.
- Clinical Outlook:
- Lasofoxifene: The Phase 3 ELAINE-3 trial for metastatic breast cancer is ongoing. Enrollment of 495 of ~600 participants is complete as of the filing date, with completion expected in Q4 2026 and topline data anticipated in H2 2027.
- Brelgometon: Phase 1 for ALS is complete. Planning for a Phase 2 proof-of-concept trial is underway, with an update expected after ELAINE-3 enrollment concludes.
- Risks: Key risks include the high failure rate of clinical trials, the inability to raise additional capital due to S-3 ineligibility, reliance on third-party manufacturers, and potential dilution from outstanding warrants (Series A and B) issued in the December 2025 private placement.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $51.1M cash balance against the projected burn rate, given the explicit "substantial doubt" regarding the 12-month going concern.
- Form S-3 Status: Confirm the timeline for regaining Form S-3 eligibility (currently restricted until December 2026) and its impact on future fundraising capabilities.
- ELAINE-3 Trial Progress: Monitor enrollment completion and the timing of the futility analysis, which could impact the continuation of the trial.
- Warrant Exercise Conditions: Review the specific triggers for the Series A and Series B warrants issued in the December 2025 private placement, as their exercise could provide up to $146.2M in additional capital but is contingent on trial milestones or FDA actions.
- Milestone Liability: Assess the probability-weighted fair value of the $14.4M milestone liability to Sermonix and the potential cash outflow if milestones are met.